X0306 4 2020-01-22 false 0001689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN 0001262325 AGUIAR ERIC C/O AISLING CAPITAL LLC 888 SEVENTH AVENUE, 12TH FLOOR NEW YORK NY 10106 true false false false Common Shares 2020-01-22 4 M false 771.00 32.42 A 2021.00 I By Spouse Common Shares 2020-01-22 4 M false 1250.00 37.54 A 3271.00 I By Spouse Common Shares 2020-01-22 4 S false 500.00 54.9717 D 2771.00 I By Spouse Common Shares 2020-01-22 4 S false 500.00 55.991 D 2271.00 I By Spouse Common Shares 2020-01-22 4 S false 671.00 56.9943 D 1600.00 I By Spouse Common Shares 2020-01-22 4 S false 200.00 57.995 D 1400.00 I By Spouse Common Shares 2020-01-22 4 S false 150.00 58.8573 D 1250.00 I By Spouse Employee Stock Option (Right to Buy) 37.54 2020-01-22 4 M false 1250.00 0.00 D 2027-09-04 Common Shares 1250.00 2500.00 I By Spouse Employee Stock Option (Right to Buy) 32.42 2020-01-22 4 M false 771.00 0.00 D 2028-11-19 Common Shares 771.00 22500.00 I By Spouse These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person's spouse. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.38 - $55.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.39 - $56.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.41 - $57.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.70 - $58.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.70 - $59.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. The option, representing a right to purchase a total of 5,000 shares was granted on September 5, 2017, vesting in four equal installments on September 5, 2018, 2019, 2020 and 2021, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 1,250 shares on November 22, 2019. This employee stock option is held by the Reporting Person's spouse. The option, representing a right to purchase a total of 30,000 shares was granted on November 20, 2018, vesting in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the option holder's continuous service with the Issuer at each vesting date. The optionholder previously exercised the option with respect to 6,729 shares on November 20, 2019. /s/ Jim Engelhart, Attorney-in-fact 2020-01-24